Centro de Invesigaciones sobre Porfirinas y Porfirias (CIPYP), CONICET and Hospital de Clinicas José de San Martin, University of Buenos Aires Córdoba 2351 ler subsuelo, Argentina.
Curr Med Chem. 2011;18(16):2486-515. doi: 10.2174/092986711795843272.
Photodynamic therapy (PDT) involves the administration of a photosensitizer (PS) followed by illumination with visible light, leading to generation of reactive oxygen species. The mechanisms of resistance to PDT ascribed to the PS may be shared with the general mechanisms of drug resistance, and are related to altered drug uptake and efflux rates or altered intracellular trafficking. As a second step, an increased inactivation of oxygen reactive species is also associated to PDT resistance via antioxidant detoxifying enzymes and activation of heat shock proteins. Induction of stress response genes also occurs after PDT, resulting in modulation of proliferation, cell detachment and inducing survival pathways among other multiple extracellular signalling events. In addition, an increased repair of induced damage to proteins, membranes and occasionally to DNA may happen. PDT-induced tissue hypoxia as a result of vascular damage and photochemical oxygen consumption may also contribute to the appearance of resistant cells. The structure of the PS is believed to be a key point in the development of resistance, being probably related to its particular subcellular localization. Although most of the features have already been described for chemoresistance, in many cases, no cross-resistance between PDT and chemotherapy has been reported. These findings are in line with the enhancement of PDT efficacy by combination with chemotherapy. The study of cross resistance in cells with developed resistance against a particular PS challenged against other PS is also highly complex and comprises different mechanisms. In this review we will classify the different features observed in PDT resistance, leading to a comparison with the mechanisms most commonly found in chemo resistant cells.
光动力疗法(PDT)涉及光敏剂(PS)的给药,随后用可见光照射,导致活性氧的产生。归因于 PS 的 PDT 耐药机制可能与一般耐药机制共享,并与改变的药物摄取和外排率或改变的细胞内转运有关。作为第二步,通过抗氧化解毒酶和热休克蛋白的激活,氧反应性物质的灭活增加也与 PDT 耐药性相关。PDT 后还会诱导应激反应基因的表达,从而导致增殖、细胞脱落的调节,并诱导存活途径以及其他多种细胞外信号事件。此外,还可能发生诱导的蛋白质、膜和偶尔 DNA 损伤的修复增加。血管损伤和光化学耗氧量导致的 PDT 诱导的组织缺氧也可能导致耐药细胞的出现。PS 的结构被认为是耐药性发展的关键点,可能与其特定的亚细胞定位有关。尽管大多数特征已经在化学耐药性中描述过,但在许多情况下,PDT 和化学疗法之间没有交叉耐药性的报道。这些发现与通过与化学疗法联合增强 PDT 疗效一致。对针对特定 PS 发展出耐药性的细胞进行交叉耐药性研究,以对抗其他 PS,也是非常复杂的,包括不同的机制。在这篇综述中,我们将对观察到的 PDT 耐药性的不同特征进行分类,以与化学耐药细胞中最常见的机制进行比较。